Chronic oxytocin administration stimulates the oxytocinergic system in children with autism

Nat Commun. 2024 Jan 2;15(1):58. doi: 10.1038/s41467-023-44334-4.

Abstract

Clinical efficacy of intranasal administration of oxytocin is increasingly explored in autism spectrum disorder, but to date, the biological effects of chronic administration regimes on endogenous oxytocinergic function are largely unknown. Here exploratory biological assessments from a completed randomized, placebo-controlled trial showed that children with autism (n = 79, 16 females) receiving intranasal oxytocin for four weeks (12 IU, twice daily) displayed significantly higher salivary oxytocin levels 24 hours after the last oxytocin nasal spray administration, but no longer at a four-week follow up session. Regarding salivary oxytocin receptor gene (OXTR) epigenetics (DNA-methylation), oxytocin-induced reductions in OXTR DNA-methylation were observed, suggesting a facilitation of oxytocin receptor expression in the oxytocin compared to the placebo group. Notably, heightened oxytocin levels post-treatment were significantly associated with reduced OXTR DNA-methylation and improved feelings of secure attachment. These findings indicate that four weeks of chronic oxytocin administration stimulated the endogenous oxytocinergic system in children with autism.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Intranasal
  • Autism Spectrum Disorder* / drug therapy
  • Autistic Disorder* / drug therapy
  • Child
  • DNA
  • Female
  • Humans
  • Oxytocin / metabolism
  • Receptors, Oxytocin / genetics

Substances

  • Oxytocin
  • Receptors, Oxytocin
  • DNA